Arrowstreet Capital
DAWN

Arrowstreet Capital’s Day One Biopharmaceuticals DAWN Stock Holding History

Arrowstreet Capital’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$328K Sell
15,294
-239,728
-94% -$3.38M ﹤0.01% 1724
2025
Q4 		$2.38M Buy
+255,022
New +$2.13M ﹤0.01% 1357

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Arrowstreet Capital's DAWN Position: Q1 2026 in Review

Arrowstreet Capital reduced its Day One Biopharmaceuticals (DAWN) stake by 94% in Q1 2026, selling an estimated $3.38M and leaving 15,294 shares worth $328K. The position accounts for ﹤0.01% of the portfolio, ranked #1724.

Arrowstreet Capital first reported a position in DAWN in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.38M in Q4 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Arrowstreet Capital held 15,294 shares of Day One Biopharmaceuticals worth $328K as of Q1 2026.
  • Arrowstreet Capital sold 239,728 Day One Biopharmaceuticals shares in Q1 2026, an estimated $3.38M.
  • Day One Biopharmaceuticals made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1724 holding.
  • Arrowstreet Capital first reported a position in Day One Biopharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Arrowstreet Capital's Day One Biopharmaceuticals position peaked at $2.38M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.